Mesenchymal stem cells therapy (Therapeutic Solutions International)

N/A

Report date: 2026/03/19 20:00:18

Base Information

Drug NameMesenchymal stem cells therapy (Therapeutic Solutions International)
Drug Alias NameJadiCellJadiCells™Mesenchymal stem cellsUniversal Donor Stem Cell DrugAllogeneic umbilical cord mesenchymal stem cells therapy (Therapeutic Solutions International)
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacementsInterleukin-10 inhibitorsInterleukin-17 inhibitors
TargetsInterleukin-10Interleukin-17
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesJadi Cell LLC
China Registration ClassN/A

Develop Information

Active CompaniesBreathe Biologics IncTherapeutic Solutions International Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A